RxDoctor Payments Data

Matthew Lawson, DO

Family Medicine · Oxford, MINPI 1306330154

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 18 payments — averaging $63.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$246
  • Pfizer$238
  • Grifols USA, LLC$143
  • AbbVie$132
  • AstraZeneca$125
  • Teva Pharmaceuticals USA, Inc.$120
  • plus $133 from 5 others

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$23,696
Medicare patients
99
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$30,771
OzempicSemaglutide24$24,857
TrulicityDulaglutide20$21,821
EliquisApixaban16$14,051
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,304
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,648
Atorvastatin Calcium213$3,247
Tolterodine Tartrate ErTolterodine Tartrate13$2,424
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,527
Albuterol Sulfate HfaAlbuterol Sulfate46$1,311
Losartan Potassium105$1,304
Omeprazole78$1,217
Novolog FlexpenInsulin Aspart18$1,199
Rosuvastatin Calcium74$1,131
Duloxetine Hcl43$1,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$238$14,05116 claims
GSKTrelegy Ellipta$13$12,30416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Oxford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →